Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1 18Phase 3 16Phase 1/2 9Phase 2/3 3Phase NA 2Phase EARLY_PHASE1 1Phase 4 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Stomach Neoplasms 1

Interventions

Capecitabine 16Paclitaxel 12Docetaxel 10Cyclophosphamide 10Epirubicin 8Gemcitabine 7Letrozole 6Doxorubicin 6Carboplatin 6Trastuzumab 5Vinorelbine 4Cisplatin 4pertuzumab 3exemestane 3Neoadjuvant Therapy 3Drug Therapy 3Ado-Trastuzumab Emtansine 3AC protocol 3130-nm albumin-bound paclitaxel 3apatinib 2Zoledronic Acid 2Thiotepa 2Taxes 2Tamoxifen 2Standard of Care 2Radiosurgery 2Melatonin 2Lapatinib 2Injections 2Goserelin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Neoplasms × Ado-Trastuzumab Emtansine × Clear all
NCT05288777 2025-04-18

Breast53

University of Virginia

Phase 2/3 Recruiting
45 enrolled
Breast

Breast Neoplasms

NCT04924699 2023-03-17

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Shanghai Miracogen Inc.

Phase 2/3 Unknown
350 enrolled
Breast

Breast Neoplasms

NCT02568839 2020-08-13

PREDIX HER2

Karolinska University Hospital

Phase 2/3 Active not recruiting
202 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡